[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
36 patients with cervical carcinoma were treated with cytostatic drugs in our department between January 1986 and December 1988. Following histological diagnosis by staging laparotomy or by means of a scalenous biopsy, 12 patients received primary chemotherapy and 3 patients received adjuvant chemotherapy following a radical hysterectomy, because of the histological extent of the disease. Twenty-one patients were treated by chemotherapy because of recurrent disease. Treatment consisted at first of a combination of cisplatin and etoposide, followed in August 1987 with a combination of carboplatin and ifosfamide. More than 90% of patients, the SCC, CEA or both tumour markers were elevated before the treatment, so that the course of the tumour markers during chemotherapy could be followed. All patients showed primary response to therapy, the tumour marker levels fell rapidly to normal after one or two cycles. None of these patients showed tumour progression while the tumour marker levels were within the normal range. Clinical remission was not obtained in those patients with levels, which remained high or rose again following an initial decrease. After only two cycles of chemotherapy, levels began to rise further and continuation of therapy did not seem justified. Chemotherapy is often the only available therapy for advanced cervical carcinoma or recurrent disease, even though the results of treatment in squamous cell carcinoma remain poor. The course of SCC and/or CEA levels can help in an early decision, whether or not the patient would profit from a continuation of the therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Meier
W
W
Frauenklinik, Ludwig-Maximilians-Universität München.
Eiermann
W
W
Stieber
P
P
Fateh-Moghadam
A
A
Hepp
H
H
D000230:Adenocarcinoma / Q000188:drug therapy*; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D016190:Carboplatin; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D015843:Serpins; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D009944:Organoplatinum Compounds; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide
SCC-und CEA-Verlauf als Prognosekriterium für das Ansprechen einer Chemotherapie beim Zervixkarzinom.